| Literature DB >> 25298883 |
Gabriela Alejandra Sosa1, Soledad Bell1, Silvia Beatriz Christiansen2, Marcelo Pietrani3, Mariela Glerean1, Monica Loto1, Soledad Lovazzano1, Antonio Carrizo4, Pablo Ajler4, Patricia Fainstein Day1.
Abstract
UNLABELLED: IgG4-related hypophysitis is a recently described entity belonging to the group of IgG4-related diseases. Many other organs can also be affected, and it is more common in older men. To date, 32 cases of IgG4-related hypophysitis have been reported in the literature, 11 of which included confirmatory tissue biopsy and the majority affecting multiple organs. The aim of this report is to present two cases of biopsy-proven IgG4-related hypophysitis occurring in two young female patients with no evidence of involvement of other organs at the time of diagnosis. LEARNING POINTS: IgG4-related hypophysitis belongs to the group of IgG4-related diseases, and is a fibro-inflammatory condition characterized by dense lymphoplasmacytic infiltrates rich in IgG4-positive plasma cells and storiform fibrosis.It is more common in older men, but young women may also present this type of hypophysitis.Although involvement of other organs is frequent, isolated pituitary disease is possible.Frequent clinical manifestations include anterior hypopituitarism and/or diabetes insipidus.THE DIAGNOSIS MAY BE CONFIRMED WITH ANY OF THE FOLLOWING CRITERIA: a pituitary biopsy with lymphoplasmacytic infiltrates, with more than ten IgG4-positive cells; a sellar mass and/or thickened pituitary stalk and a biopsy-proven involvement of another organ; a sellar mass and/or thickened pituitary stalk and IgG4 serum levels >140 mg/dl and sellar mass reduction and symptom improvement after corticosteroid treatment.Glucocorticoids are recommended as first-line therapy.Entities:
Year: 2014 PMID: 25298883 PMCID: PMC4174594 DOI: 10.1530/EDM-14-0062
Source DB: PubMed Journal: Endocrinol Diabetes Metab Case Rep ISSN: 2052-0573
Pre-operative laboratory results of case 1
|
|
|
|---|---|
| Haematocrit (37–47%) | 32% |
| Haemoglobin (11.5–16 g/dl) | 11.2 g/dl |
| White blood cells (5000–10 000/mm3) | 5680/mm3 |
| Glycaemia (70–110 mg/dl) | 88 mg/dl |
| Creatinine (0.5–1.2 ng/dl) | 0.79 ng/dl |
| Sodium (135–145 mmol/l) | 144 mmol/l |
| Potassium (3.5–5 mmol/l) | 3.4 mmol/l |
| Total bilirrubin (0.1–1.4 ng/dl) | 0.5 ng/dl |
| Alkaline phosphatase (31–100 UI/l) | 87 UI/l |
| Aspartate aminotransferase (AST, 10–42 UI/l) | 32 UI/l |
| Alanine aminotrasferase (ALT, 10–40 UI/l) | 25 UI/l |
| Albumin (3.2–5 g/dl) | 4.6 g/dl |
| Prolactin (5–25 ng/ml) | 26 ng/ml |
| Luteinizing hormone (LH, 1–18 mU/ml) | 1.3 mU/ml |
| Follicle-stimulating hormone (FSH, 4–13 mU/ml) | 2.8 mU/ml |
| Estradiol (35–169 pg/ml) | <20 pg/ml |
| Growth hormone (<5 ng/ml) | 0.24 ng/ml |
| IGF1 (117–329 ng/ml) | 100 ng/ml |
| Baseline cortisol (5–25 μg/dl) | 9 μg/dl |
| Salivary cortisol 2300 h (0.7–5 nmol/l) | 0.02 nmol/l |
| Free urinary cortisol 2400 h (<100 μg/2400 h) | 20 μg/2400 h |
| Tyrotrophin (0.47–4.64 μU/ml) | 0.6 μU/ml |
| Free thyroxine (0.7–1.8 ng/dl) | 1.7 ng/dl |
| Anti TPO (<40 UI/ml) | 0.9 UI/ml |
NV, normal values; anti-TPO, anti-thyroperoxidase antibody; IGF1, insulin growth factor 1.
No GH stimulation test was performed.
Figure 1(A and B) Preoperative gadolinium-enhanced T1 weighted MRI: lesion measuring 19 mm vertical length near the optic chiasm, with irregular peripheral enhancement. (C and D) Postoperative gadolinium-enhanced T1 weighted MRI: persistence of heterogeneous asymmetrical mass with infiltration of the sphenoidal sinus near the optic chiasm. (E and F) Nonenhanced MRI: significant reduction in tumor size 4 months after starting meprednisone treatment.
Figure 2(A) Pituitary gland pathology report: dense inflammatory lymphoplasmacytic infiltrates. (B) IgG4-positive immunostaining in more than ten plasma cells per high power field (arrows, 40×).
Figure 3(A and B) Preoperative nonenhanced MRI: an extensive intrasellar lesion expanding into suprasellar region was found, with signs of bleeding, compression and optic chiasm displacement. (C and D) Postoperative nonenhanced MRI under meprednisone treatment showed significant reduction in sellar mass size.
Pre-operative laboratory results of case 2
|
|
|
|---|---|
| Haematocrit (37–47%) | 40% |
| Haemoglobin (11.5–16 g/dl) | 13.6 g/dl |
| White cell blood count (5000–10 000/mm3) | 4620/mm3 |
| Glycaemia (70–110 mg/dl) | 82 mg/dl |
| Creatinine (0.5–1.2 ng/dl) | 0.87 ng/dl |
| Sodium (135–145 mmol/l) | 140 mmol/l |
| Potassium (3.5–5 mmol/l) | 3.4 mmol/l |
| Total bilirrubin (0.1–1.4 ng/dl) | 0.7 ng/dl |
| Alkaline phosphatase (31–100 UI/l) | 49 UI/l |
| Aspartate aminotransferase (10–42 UI/l) | 14 UI/l |
| Alanine aminotrasferase (10–40 UI/l) | 21 UI/l |
| Albumin (3.2–5 g/dl) | 4.1 g/dl |
| Luteinizing hormone (1–18 mU/ml) | 0.19 mU/ml |
| Follicle-stimulating hormone (4–13 mU/ml) | 1.26 mU/ml |
| Estradiol (35–169 pg/ml) | <25 pg/ml |
| Thyrotrophin (0.47–4.64 μU/ml) | <0.01 μU/ml |
| Free thyroxine (0.7–1.8 ng/dl) | 0.83 ng/dl |
| IGF1 (117–329 ng/ml) | 194 ng/ml |
| Cortisol (5–25 μg/dl) | 4.4 μg/dl |
| Adreno corticotropin (10–46 pg/ml) | <5 |
| Prolactin (5–25 ng/ml) | 125 ng/ml |
NV, normal value; IGF1, insulin growth factor 1.
Under desmopressin treatment.
Figure 4(A) Pituitary gland histopathology report: dense lymphoplasmacytic inflammatory infiltrates. (B) IgG4-positive immunostaining in more than ten plasma cells per high power field (arrows).